SLCO1B1
Introduction[edit | edit source]
The SLCO1B1 gene encodes the solute carrier organic anion transporter family member 1B1, a protein that plays a crucial role in the hepatic uptake of various endogenous and exogenous compounds, including drugs. This transporter is primarily expressed in the liver and is involved in the clearance of drugs from the bloodstream, impacting their pharmacokinetics and pharmacodynamics.
Structure and Function[edit | edit source]
SLCO1B1 is a member of the solute carrier family and is located on chromosome 12 (12p12.1). The protein product of SLCO1B1, known as OATP1B1, is an integral membrane protein that facilitates the sodium-independent uptake of a wide range of organic anions into hepatocytes. This includes bile acids, bilirubin, and numerous drugs such as statins, which are used to lower cholesterol levels.
Genetic Variants[edit | edit source]
Several polymorphisms in the SLCO1B1 gene have been identified, with significant implications for drug metabolism. The most studied variant is the c.521T>C (p.Val174Ala) polymorphism, which is associated with reduced transporter activity. Individuals carrying this variant may experience altered drug clearance, leading to increased plasma concentrations and a higher risk of adverse drug reactions.
Clinical Significance[edit | edit source]
The SLCO1B1 gene is of particular interest in the field of pharmacogenomics, as its variants can influence the efficacy and toxicity of drugs. For example, reduced function variants of SLCO1B1 are linked to an increased risk of statin-induced myopathy, a condition characterized by muscle pain and weakness. Pharmacogenetic testing for SLCO1B1 variants can guide personalized medicine approaches, optimizing drug therapy based on an individual's genetic makeup.
Research and Developments[edit | edit source]
Ongoing research aims to further elucidate the role of SLCO1B1 in drug metabolism and its potential as a target for therapeutic intervention. Studies are also exploring the impact of SLCO1B1 variants on the pharmacokinetics of emerging drugs and their implications for drug development.
Also see[edit | edit source]
References[edit | edit source]
External links[edit | edit source]
| Key components | |
|---|---|
| Fields | |
| Related topics | |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
